These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 37318657)
1. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma. Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657 [TBL] [Abstract][Full Text] [Related]
2. PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma. Liu M; Yang M; Zhang B; Xia S; Zhao J; Yan L; Ren Y; Guo H; Zhao J J Mol Med (Berl); 2024 Jul; 102(7):899-912. PubMed ID: 38739269 [TBL] [Abstract][Full Text] [Related]
3. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542 [TBL] [Abstract][Full Text] [Related]
4. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782 [TBL] [Abstract][Full Text] [Related]
5. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer. Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X Front Immunol; 2022; 13():834142. PubMed ID: 35242138 [TBL] [Abstract][Full Text] [Related]
6. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer. Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392 [TBL] [Abstract][Full Text] [Related]
7. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938 [TBL] [Abstract][Full Text] [Related]
8. EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma. Bai H; Duan J; Li C; Xie W; Fang W; Xu Y; Wang G; Wan R; Sun J; Xu J; Wang X; Fei K; Zhao Z; Cai S; Zhang L; Wang J; Wang Z J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303576 [TBL] [Abstract][Full Text] [Related]
9. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274 [TBL] [Abstract][Full Text] [Related]
10. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079 [TBL] [Abstract][Full Text] [Related]
11. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739 [TBL] [Abstract][Full Text] [Related]
12. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
13. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410 [TBL] [Abstract][Full Text] [Related]
14. Ji W; Niu X; Yu Y; Li Z; Gu L; Lu S Front Immunol; 2022; 13():955800. PubMed ID: 36405701 [TBL] [Abstract][Full Text] [Related]
15. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J Front Immunol; 2020; 11():1173. PubMed ID: 32587591 [No Abstract] [Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
17. Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878 [TBL] [Abstract][Full Text] [Related]
18. EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. Huang W; Lin A; Luo P; Liu Y; Xu W; Zhu W; Wei T; Lyu Q; Guo L; Zhang J Cancer Gene Ther; 2021 Aug; 28(7-8):864-874. PubMed ID: 32759987 [TBL] [Abstract][Full Text] [Related]
19. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895 [TBL] [Abstract][Full Text] [Related]
20. Identification of Deleterious Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]